Isabel de Rojas-P

Isabel de Rojas-P

Auto-generated profile, based on publicly available information

Isabel de Rojas-P

Universitat Autónoma de Barcelona

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in Epigenomics
Verified
Journal Article
Open access
MFMaria Farina-Morillas
Maria Farina-Morillas
LOLaia Ollé-Monràs
Laia Ollé-Monràs
SMSilvana Ce Maas
Silvana Ce Maas
IRIsabel de Rojas-P
Isabel de Rojas-P
Miguel F SeguraMiguel F Segura
Miguel F Segura
JSJose A. Seoane
Jose A. Seoane
Cancer treatment is an ongoing challenge, as directly targeting oncogenic drivers is often unfeasible in many patients due to the lack of druggable targets. This has led to the exploration of alternative strategies, such as exploiting synthetic lethality (SL) relationships between genes. SL facilitates the indirect targeting of oncogenic drivers, as exemplified by the clinical success of PARP inhibitors against BRCA-mutated tumors. Advances in high-throughput perturbation screens and multi-omics technologies have deepened our understanding of SL relationships, while computational models enhance SL predictions to better reflect biological complexity. However, while numerous experimental and computational methods have been developed to identify SL interactions, difficulties remain in translating these findings into clinical applications.This review combines recent progress on SL relationships in cancer with emerging insights into epigenetic regulation, highlighting how epigenetic drugs (epidrugs) can provide new opportunities for targeted interventions, offering a way to minimize off-target effects and enhance therapeutic precision. To advance SL-based therapies, efforts must focus not only on identifying new SL interactions but also on consolidating existing knowledge and integrating experimental and computational approaches to characterize the vulnerabilities of cancer cells. Strengthening this foundation will be critical for the effective development of SL-based cancer treatments.